The safety and immunogenicity of a protein-based tetravalent vaccine SCTV01E that
contains spike protein ectodomain (S-ECD) of Alpha, Beta, Delta and Omicron BA. 1 are …

Background Booster vaccination is an efficient way to address the waning protection of
vaccines and immune escape of SARS-CoV-2 variants. We aimed to assess the safety and …

The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
has caused more than 1 million deaths in the first 6 months of the pandemic and huge …

Background We evaluated an inactivated SARS-CoV-2 vaccine for immunogenicity and
safety in adults aged 18-59 years. Methods In this randomized, double-blinded and …

Background Efficacious vaccines are urgently needed to contain the ongoing coronavirus
disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome …

Background COVID-19 vaccines approved in the UK are highly effective in general
population cohorts, however, data on effectiveness amongst individuals with clinical …

Background CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown
to be well tolerated with a good safety profile in individuals aged 18 years and older in …

Individuals with compromised immune systems, whether because of immunodeficiency or
immuno suppressive therapy, are among those most susceptible to COVID19. In fact, people …

Background Given the importance of flexible use of different COVID-19 vaccines within the
same schedule to facilitate rapid deployment, we studied mixed priming schedules …

Background Vaccine effectiveness against COVID-19 beyond 6 months remains
incompletely understood. We aimed to investigate the effectiveness of COVID-19 …